Reuters Health Report

If you are having trouble viewing this email or would like to view it in your web browser, CLICK HERE

Good Morning Postlinuxeg, WED 02 Jun 2010 
 
Butt test shows U.S. cigarettes high in chemicals
Caffeine addicts get no real perk from morning cup
Cancer will kill 13.2 million a year by 2030: U.N.
Genes and lifestyle pose separate breast cancer risks
Italy joins Europe-wide move to cut drug costs
Americans prefer drugs for depression: survey
Glaxo settles more Avandia lawsuits in U.S.
FDA approves Amgen osteoporosis drug
African mining may be driving TB epidemic: study
Chocolate may cut cholesterol but only in some people: study

Butt test shows U.S. cigarettes high in chemicals
June 01, 2010 05:51 PM ET
WASHINGTON (Reuters) - Americans inhale more cancer-causing agents with their cigarettes, probably because of the tobacco blend, while smokers in Canada, Britain and Australia get less, U.S. researchers reported on Tuesday.

Full Article
Caffeine addicts get no real perk from morning cup
June 02, 2010 09:31 AM ET
LONDON (Reuters) - Caffeine addiction is such a downer that regular coffee drinkers may get no real pick-me-up from their morning cup, according to a study by British scientists.

Full Article
Cancer will kill 13.2 million a year by 2030: U.N.
June 01, 2010 01:20 PM ET
LONDON (Reuters) - Cancer will kill more than 13.2 million people a year by 2030, almost double the number who died from the disease in 2008, the United Nations' cancer research agency said on Tuesday.

Full Article
Genes and lifestyle pose separate breast cancer risks
June 01, 2010 07:04 PM ET
LONDON (Reuters) - Common genetic differences have a limited role in causing breast cancer and work independently of lifestyle factors such as weight, diet and breastfeeding which are still more important, British scientists said on Wednesday.

Full Article
Italy joins Europe-wide move to cut drug costs
June 02, 2010 07:33 AM ET
ROME (Reuters) - Italy is taking new steps to rein in healthcare spending and reduce the country's drugs bill by imposing a cut in generic drug prices and curbs on reimbursement for more expensive medicines.

Full Article
Americans prefer drugs for depression: survey
June 01, 2010 10:48 AM ET
WASHINGTON (Reuters) - Americans prefer drugs to talk therapy for depression, with nearly 80 percent taking a pill for the condition, Consumer Reports said on Tuesday.

Full Article
Glaxo settles more Avandia lawsuits in U.S.
June 01, 2010 06:47 AM ET
LONDON (Reuters) - GlaxoSmithKline Plc has settled thousands more lawsuits brought by patients alleging its Avandia diabetes drug caused heart attacks, in a move that may defuse potentially massive claims over the medicine.

Full Article
FDA approves Amgen osteoporosis drug
June 01, 2010 07:35 PM ET
NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc's osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.

Full Article
African mining may be driving TB epidemic: study
June 01, 2010 05:45 PM ET
LONDON (Reuters) - Poor living and working conditions for miners of gold, diamonds and other precious metals have contributed significantly to tuberculosis (TB) epidemics across Africa, scientists said on Tuesday.

Full Article
Chocolate may cut cholesterol but only in some people: study
June 01, 2010 09:02 PM ET
NEW YORK (Reuters Life!) - Eating chocolate could bring down cholesterol levels -- but only in small amounts and only in some people, according to an analysis of eight studies.

Full Article
 
 











REUTERS www.reuters.com
Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book.Details
Subscribe to other Reuters newsletters
Unsubscribe from this newsletter.


Forward to a friend Send this mailing to a friend or colleague


Reuters.com: Help and Contact Us | Advertise With Us | Mobile | Newsletters | RSS RSS Feed | Interactive TV | Labs | Reuters in Second Life | Archive | Site Index | Video Index

Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers

0 comentários: